I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Crohn\'s disease (CD) is a form of inflammatory bowel disease (IBD), which mainly involves the end of the small intestine and beginning of the colon.\[[@ref1]\] The clinical manifestations and complications of CD are complex and varied, and they make CD challenging for both patients and physicians. There have been several controversies in the coagulation status of CD. In most studies, a hypercoagulable coagulation status was present in CD patients, resulting in high risk of venous thromboembolism (VTE).\[[@ref2]\] However, other study has reported that prothrombin time (PT) was significantly higher in CD patients than in healthy controls.\[[@ref3]\]

Increasing amounts of research suggested that inflammation and coagulation were closely related and had interaction effects.\[[@ref4][@ref5][@ref6][@ref7]\] In some severe infectious events, such as intestinal fistula, the coagulation state is mainly hypocoagulable.\[[@ref8]\] Intestinal fistula is one of the common complications of CD. Because of intestinal fistula often along with abdominal infection and malnutrition, the clinical characteristics and outcomes of such patients are much different from those of patients with CD alone. Hence, the coagulation status of CD patients complicated with intestinal fistula possibly differs from that of the simple CD patients.

It is essential for CD patients who require surgical intervention, for example, CD patients complicated with intestinal fistula, to monitor their coagulation status regularly and systematically. Normal coagulation status is closely related to a favorable prognosis and offers the safety of subsequent operations. This study aimed to evaluate abnormalities in coagulation in CD patients complicated with intestinal fistula and to investigate whether the coagulation status changed is associated with intestinal fistula of CD.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Ethics Committee of Jinling Hospital. Informed consent was obtained from all patients via telephone before their enrollment in this study.

Patients {#sec2-2}
--------

Data were retrospectively analyzed for 190 patients with a definitive diagnosis of CD, who were registered in the Department of General Surgery at Jinling Hospital between January 2014 and September 2015. A definitive diagnosis of CD was based on the results of multiple examinations, such as colonoscopy, small bowel capsule endoscopy, enteroscopy, gastroscope, computed tomography, enterography, histopathological examination, and blood tests (including routine blood examination, erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\], and autoimmune-related antibodies). Overall, 31 patients were excluded from this study, including 20 who did not undergo coagulation function tests, eight who had received blood transfusions or hemostatic drugs, and three who were under 16 years of age when they were diagnosed.

The patients' data were collected from the electronic database at Jinling Hospital. The data included gender, age, smoking status (yes or no), regular rest (yes or no, meaning that work and rest times were relatively fixed), body mass index (BMI), disease locations (small bowel only, colon only, or small bowel and colon), operation history (ileocecal resection, other small bowel resection, or colon resection), intestinal fistula (yes or no, meaning that the patient had complications of CD that needed surgical intervention), and current medication (mesalazine, sulfasalazine, or azathioprine).

The study group was stratified by complicated with or without intestinal fistula. The diagnosis of intestinal fistula was made by the findings of sonography, abdominal CT, barium meal or enema, and enteroscopy or colonoscopy. All the fistulas included were enterocutaneous fistulas. Each group was stratified by gender because there are differences between clinical manifestations of CD and coagulation function in males and females. Demographics, clinical characteristics, and initial admission laboratory indices were compared between groups and subgroups.

Blood samples {#sec2-3}
-------------

After initial admission to the hospital and 7 days after intestinal fistula resections (only performed in the postoperative patients), early morning fasting venous blood samples were obtained from each patient after a 12-h fast. Laboratory indices were tested, including CRP, ESR, platelets (PLTs), mean platelet volume (MPV), PT, fibrinogen (FIB), activated partial thromboplastin time (APTT), thrombin time (TT), and international normalized ratio (INR). All of the samples were analyzed in duplicate at the Department of Clinical Laboratory, Jinling Hospital.

Statistical analysis {#sec2-4}
--------------------

All statistical analyses were performed using the statistical software SPSS Statistics Version 20.0 (IBM, Chicago, IL, USA). Categorical variables were presented as a percentage of the total. Quantitative variables were summarized as mean ± standard deviation (SD). Student\'s *t*-test (for numerical data) and the Wilcoxon rank-sum test (for nonparametric data) were used to compare differences between the two groups. Differences in the frequencies for categorical data were compared using the Chi-square test or Fisher\'s exact test in the case of a small sample size (*n* \< 5 per group). Multivariate logistic regression analyses were performed to determine the variables associated with complications, and odds ratios (*OR*s) were estimated with the associated *P* values. A *P* \< 0.05 was considered to indicate statistical significance.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Baseline clinical characteristics of the overall study group {#sec2-5}
------------------------------------------------------------

Baseline clinical characteristics of the overall study group are shown in [Table 1](#T1){ref-type="table"}. A significant difference could be observed in gender distribution between intestinal fistula and nonintestinal fistula groups (female: 26.0% vs. 43.0%, *P* = 0.025). There was no significant difference in age, smoking status, regular test, BMI, disease locations, or current medication between the two groups (all *P* \> 0.05). A higher rate of operation history was discovered in the intestinal fistula group (58.9%) than that of the nonintestinal fistula group (25.6%, *P* \< 0.001), especially for other small bowel resection (31.5% vs. 17.4%, *P* = 0.038) and colon resection (20.5% vs. 3.5%, *P* = 0.001).

###### 

Baseline and clinical characteristics of the overall study group

  Characteristics                           Intestinal fistula group (*n* = 73)   Nonintestinal fistula group (*n* = 86)   Statistical values   *P*
  ----------------------------------------- ------------------------------------- ---------------------------------------- -------------------- ---------
  Female                                    19 (26.0)                             37 (43.0)                                4.999^†^             0.025
  Age (years)                               35.6 ± 12.7                           32.4 ± 11.7                              1.685                0.094
  Smoker                                    16 (21.9)                             17 (19.8)                                0.111^†^             0.739
  Regular rest                              71 (97.3)                             83 (96.5)                                0.073^†^             1.000
  BMI (kg/m^2^)                             18.5 ± 2.7                            18.2 ± 2.9                               0.500                0.618
  Disease locations                                                                                                                             
   Only small bowel                         36 (49.3)                             35 (40.7)                                1.186^†^             0.276
   Only colon                               13 (17.8)                             22 (25.6)                                1.390^†^             0.238
   Small bowel and colon                    24 (32.9)                             29 (33.7)                                0.013^†^             0.910
  Operation history\*                       43 (58.9)                             22 (25.6)                                18.141^†^            \<0.001
   Ileocecal resection                      17 (23.3)                             10 (11.6)                                3.808^†^             0.051
   Other small bowel resection              23 (31.5)                             15 (17.4)                                4.295^†^             0.038
   Colon resection                          15 (20.5)                             3 (3.5)                                  11.446^†^            0.001
  Current medication                                                                                                                            
   Mesalazine                               15 (20.5)                             10 (11.6)                                2.371^†^             0.124
   Sulfasalazine                            4 (5.5)                               3 (3.5)                                  0.372^†^             1.000
  Laboratory indexes of initial admission                                                                                                       
   CRP (mg/L)                               42.17 ± 58.56                         27.81 ± 42.71                            1.727                0.087
   ESR (mm/h)                               29.06 ± 24.06                         25.88 ± 23.73                            0.746                0.457
   PLT (×10^9^/L)                           262.53 ± 94.36                        310.36 ± 131.91                          −2.646               0.009
   MPV (fl)                                 9.53 ± 1.58                           9.15 ± 1.41                              1.626                0.106
   PT (s)                                   13.18 ± 1.51                          12.13 ± 1.27                             4.619                \<0.001
   FIB (g/L)                                3.61 ± 1.05                           3.50 ± 1.07                              0.607                0.545
   APTT (s)                                 35.91 ± 9.95                          32.75 ± 6.08                             2.374                0.019
   TT (s)                                   17.67 ± 1.79                          17.50 ± 1.50                             0.605                0.546
   INR                                      1.17 ± 0.24                           1.05 ± 0.11                              3.809                \<0.001

Data are shown as *n* (%) or mean ± SD. \*As a patient may have undergone several operations, the percentage totals more than 100%. ^†^Wilcoxon rank-sum test, otherwise Student\'s *t*-test. BMI: Body mass index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; PLT: Platelet; MPV: Mean platelet volume; PT: Prothrombin time; FIB: Fibrinogen; APTT: Activated partial thromboplastin time; TT: Thrombin time; INR: International normalized ratio; SD: Standard deviation.

As shown in [Table 1](#T1){ref-type="table"}, PT in intestinal fistula group (13.18 ± 1.51 s) was significantly longer than that of nonintestinal fistula group (12.13 ± 1.27 s, *P* \< 0.001). Similarly, APTT was markedly longer (35.91 ± 9.95 s vs. 32.75 ± 6.08 s, *P* = 0.019) and INR was higher (1.17 ± 0.24 vs. 1.05 ± 0.11, *P* \< 0.001) in intestinal fistula group, compared with nonintestinal fistula group. In addition, PLT count in intestinal fistula group was much lower than that of nonintestinal fistula group (\[262.53 ± 94.36\] × 10^9^/L vs. \[310.36 ± 131.91\] × 10^9^/L, *P* = 0.009). There was no significant difference in CRP, ESR, MPV, FIB, and TT between the two groups.

Clinical characteristics of the study subgroups stratified by gender {#sec2-6}
--------------------------------------------------------------------

No significant differences were found in age, regular test, BMI, disease locations, current medication, or some laboratory indexes (such as CRP, ESR, FIB, and TT) between two subgroups of females and males.

In females, intestinal fistula subgroup tended to have more operation history than nonintestinal fistula subgroup (52.6% vs. 18.9%, *P* = 0.009). The PT in intestinal fistula group (12.61 ± 0.73 s) was significantly longer than that in nonintestinal fistula subgroup (11.56 ± 1.21 s, *P* = 0.001). Similarly, INR was higher in intestinal fistula subgroup, compared with nonintestinal fistula subgroup (1.19 ± 0.41 vs. 1.01 ± 0.10, *P* = 0.021). In addition, MPV was also higher in intestinal fistula subgroup (10.13 ± 1.77 fl vs. 8.80 ± 1.39 fl, *P* = 0.003; [Table 2](#T2){ref-type="table"}).

###### 

Baseline and clinical characteristics of the female CD patients with or without intestinal fistula

  Characteristics                           Intestinal fistula female subgroup (*n* = 19)   Nonintestinal fistula female subgroup (*n* = 37)   Statistical values   *P*
  ----------------------------------------- ----------------------------------------------- -------------------------------------------------- -------------------- -------
  Age (years)                               40.5 ± 14.7                                     35.9 ± 12.8                                        1.214^†^             0.230
  Regular rest                              19 (100.0)                                      36 (97.3)                                          0.523                1.000
  BMI (kg/m^2^)                             18.6 ± 2.9                                      17.8 ± 2.6                                         0.885^†^             0.381
  Disease locations                                                                                                                                                 
   Only small bowel                         11 (57.9)                                       14 (37.8)                                          2.043                0.153
   Only colon                               2 (10.5)                                        13 (35.1)                                          3.877                0.061
   Small bowel and colon                    6 (31.6)                                        10 (27.0)                                          0.127                0.721
  Operation history\*                       10 (52.6)                                       7 (18.9)                                           6.749                0.009
   Ileocecal resection                      5 (26.3)                                        3 (8.1)                                            3.399                0.105
   Other small bowel resection              4 (21.1)                                        3 (8.1)                                            1.923                0.212
   Colon resection                          2 (10.5)                                        2 (5.4)                                            0.496                0.598
  Current medication                                                                                                                                                
   Mesalazine                               3 (15.8)                                        2 (5.4)                                            1.665                0.324
   Sulfasalazine                            1 (5.3)                                         0 (0)                                              1.983                0.339
  Laboratory indexes of initial admission                                                                                                                           
   CRP (mg/L)                               32.76 ± 49.27                                   21.77 ± 35.52                                      0.952^†^             0.345
   ESR (mm/h)                               32.87 ± 22.18                                   27.24 ± 23.40                                      0.769^†^             0.446
   PLT (×10^9^/L)                           245.32 ± 83.30                                  295.14 ± 115.46                                    −1.663^†^            0.102
   MPV (fl)                                 10.13 ± 1.77                                    8.80 ± 1.39                                        3.064^†^             0.003
   PT (s)                                   12.61 ± 0.73                                    11.56 ± 1.21                                       3.404^†^             0.001
   FIB (g/L)                                3.64 ± 0.97                                     3.23 ± 1.00                                        1.415^†^             0.164
   APTT (s)                                 32.79 ± 5.67                                    31.78 ± 6.81                                       0.542^†^             0.590
   TT (s)                                   17.78 ± 1.63                                    17.81 ± 1.13                                       −0.148^†^            0.955
   INR                                      1.19 ± 0.41                                     1.01 ± 0.10                                        0.099^†^             0.021

Data are shown as *n* (%) or mean ± SD. \*As a patient may have undergone several operations, the percentage totals more than 100%. ^†^Student\'s *t*-test, otherwise Wilcoxon rank-sum test. BMI: Body mass index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; PLT: Platelet; MPV: Mean platelet volume; PT: Prothrombin time; FIB: Fibrinogen; APTT: Activated partial thromboplastin time; TT: Thrombin time; INR: International normalized ratio; SD: Standard deviation; CD: Crohn\'s disease.

In males, intestinal fistula subgroup also tended to have more operation history than nonintestinal fistula subgroup (61.1% vs. 30.6%, *P* = 0.002). Moreover, patients in intestinal fistula subgroup had more colon resection (24.1% vs. 2.0%, *P* = 0.001), which was not consistent with results in females. PT in intestinal fistula subgroup (13.37 ± 1.66 s) was significantly longer than that of nonintestinal fistula subgroup (12.51 ± 1.17 s, *P* = 0.003). Similarly, compared with nonintestinal fistula subgroup, APTT was longer (33.39 ± 5.52 s vs. 37.01 ± 10.91 s, *P* = 0.042) and INR was higher (1.09 ± 0.99 vs. 1.16 ± 0.14, *P* = 0.003) in intestinal fistula subgroup. Furthermore, PLT count was lower in intestinal fistula subgroup (\[268.59 ± 97.96\] × 10^9^/L vs. \[321.55 ± 142.92\] × 10^9^/L, *P* = 0.029; [Table 3](#T3){ref-type="table"}).

###### 

Baseline and clinical characteristics of the male CD patients with or without intestinal fistula

  Characteristics                           Intestinal fistula male subgroup (*n* = 54)   Nonintestinal fistula male subgroup (*n* = 49)   Statistical values   *P*
  ----------------------------------------- --------------------------------------------- ------------------------------------------------ -------------------- -------
  Age (years)                               33.9 ± 11.6                                   29.7 ± 10.2                                      1.949^†^             0.054
  Smoker                                    16 (29.6)                                     17 (34.7)                                        0.303                0.582
  Regular rest                              52 (96.3)                                     47 (95.9)                                        0.010                1.000
  BMI (kg/m^2^)                             18.5 ± 2.6                                    18.6 ± 3.1                                       −0.191^†^            0.849
  Disease locations                                                                                                                                             
   Only small bowel                         25 (46.3)                                     21 (42.9)                                        0.123                0.726
   Only colon                               11 (20.4)                                     9 (18.4)                                         0.066                0.797
   Small bowel and colon                    18 (33.3)                                     19 (38.8)                                        0.331                0.565
  Operation history\*                       33 (61.1)                                     15 (30.6)                                        9.603                0.002
   Ileocecal resection                      12 (22.2)                                     7 (14.3)                                         1.076                0.300
   Other small bowel resection              19 (35.2)                                     12 (24.5)                                        1.397                0.237
   Colon resection                          13 (24.1)                                     1 (2.0)                                          10.619               0.001
  Current medication                                                                                                                                            
   Mesalazine                               12 (22.2)                                     8 (16.3)                                         0.571                0.450
   Sulfasalazine                            3 (5.6)                                       3 (6.1)                                          0.015                1.000
  Laboratory indexes of initial admission                                                                                                                       
   CRP (mg/L)                               45.54 ± 61.63                                 32.26 ± 47.16                                    1.215^†^             0.227
   ESR (mm/h)                               27.59 ± 24.86                                 25.02 ± 24.15                                    0.482^†^             0.631
   PLT (×10^9^/L)                           268.59 ± 97.96                                321.55 ± 142.92                                  −2.211^†^            0.029
   MPV (fl)                                 9.32 ± 1.47                                   9.40 ± 1.37                                      −0.284^†^            0.777
   PT (s)                                   13.37 ± 1.66                                  12.51 ± 1.17                                     3.065^†^             0.003
   FIB (g/L)                                3.60 ± 1.08                                   3.68 ± 1.08                                      −0.394^†^            0.694
   APTT (s)                                 37.01 ± 10.91                                 33.39 ± 5.52                                     2.058^†^             0.042
   TT (s)                                   17.62 ± 1.85                                  17.30 ± 1.68                                     0.904^†^             0.368
   INR                                      1.16 ± 0.14                                   1.09 ± 0.99                                      3.101^†^             0.003

Data are shown as *n* (%) or mean ± SD. ^\*^As a patient may have undergone several operations, the percentage totals more than 100%. ^†^Student\'s *t*-test, otherwise Wilcoxon rank-sum test. BMI: Body mass index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; PLT: Platelet; MPV: Mean platelet volume; PT: Prothrombin time; FIB: Fibrinogen; APTT: Activated partial thromboplastin time; TT: Thrombin time; INR: International normalized ratio; SD: Standard deviation; CD: Crohn\'s disease.

Impact of intestinal fistula on coagulation status of Crohn\'s disease patients {#sec2-7}
-------------------------------------------------------------------------------

As shown in [Table 4](#T4){ref-type="table"}, multivariate logistic regression showed that in the overall cohort, intestinal fistula was significantly associated with a prolonged PT (*OR* = 1.900, *P* \< 0.001), a reduced amount of PLT (*OR* = 0.996, *P* = 0.024), and an increased operation history (*OR* = 5.408, *P* \< 0.001). In females, intestinal fistula was also significantly associated with a prolonged PT (*OR* = 2.727, *P* = 0.014) and an increased operation history (*OR* = 5.360, *P* \< 0.001). Besides that, intestinal fistula was associated with an elevated MPV (*OR* = 1.680, *P* = 0.039). In males, intestinal fistula was significantly associated with a reduced amount of PLT (*OR* = 0.996, *P* = 0.048), an increased operation history (*OR* = 5.256, *P* = 0.007), and an elevated INR (*OR* = 717.273, *P* = 0.003).

###### 

Multivariate logistic regression analysis of risk factors for intestinal fistula of CD

  Factors              Intestinal fistula                   
  -------------------- -------------------- --------------- ---------
  Total                                                     
   Gender              0.995                0.423--2.342    0.990
   Operation history   5.408                2.372--11.148   \<0.001
   PLT                 0.996                0.993--0.999    0.024
   PT                  1.900                1.379--2.617    \<0.001
   APTT                0.992                0.929--1.059    0.816
   INR                 11.710               --              0.788
  Female                                                    
   Operation history   5.360                1.296--29.603   \<0.001
   MPV                 1.680                1.025--2.752    0.039
   PT                  2.727                1.229--6.048    0.014
   INR                 7.828                --              0.905
  Male                                                      
   Operation history   5.256                1.795--11.344   0.007
   PLT                 0.996                0.992--1.000    0.048
   PT                  0.766                --              0.951
   APTT                1.029                0.951--1.113    0.480
   INR                 717.273              --              0.003

PLT: Platelet; MPV: Mean platelet volume; PT: Prothrombin time; APTT: Activated partial thromboplastin time; INR: International normalized ratio; --: Not applicable; *OR*: Odds ratio; CD: Crohn\'s disease.

Comparisons of coagulation status in Crohn\'s disease patients before and after intestinal fistula resection {#sec2-8}
------------------------------------------------------------------------------------------------------------

Sixty-five patients received intestinal fistula resections and their coagulation status before and after operation was compared. As shown in [Table 5](#T5){ref-type="table"}, compared with the baseline, the patients showed shorter PT (13.02 ± 1.64 s vs. 12.28 ± 1.16 s, *P* = 0.006), lower INR (1.13 ± 0.14 vs. 1.08 ± 0.10, *P* = 0.003), lower PLT count (\[256.70 ± 82.47\] × 10^9^/L vs. \[221.81 ± 101.28\] × 10^9^/L, *P* = 0.004), more MPV (9.59 ± 1.59 fl vs. 10.06 ± 1.40 fl, *P* = 0.003), more FIB (3.37 ± 1.18 g/L vs. 3.92 ± 1.02 g/L, *P* = 0.009), and shorter TT (17.92 ± 1.96 s vs. 17.18 ± 1.86 s, *P* = 0.044) after intestinal fistula resections.

###### 

Coagulation status in 65 CD patients before and after intestinal fistula resection

  Laboratory indexes   Before operation   After operation   *t*      *P*
  -------------------- ------------------ ----------------- -------- -------
  CRP (mg/L)           36.15 ± 61.88      34.62 ± 35.77     0.166    0.869
  PLT (×10^9^/L)       256.70 ± 82.47     221.81 ± 101.28   3.018    0.004
  MPV (fl)             9.59 ± 1.59        10.06 ± 1.40      −3.076   0.003
  PT (s)               13.02 ± 1.64       12.28 ± 1.16      2.884    0.006
  FIB (g/L)            3.37 ± 1.18        3.92 ± 1.02       −2.757   0.009
  APTT (s)             36.51 ± 11.33      35.72 ± 5.64      0.442    0.661
  TT (s)               17.92 ± 1.96       17.18 ± 1.86      2.076    0.044
  INR                  1.13 ± 0.14        1.08 ± 0.10       3.146    0.003

Data are shown as mean ± SD. CRP: C-reactive protein; PLT: Platelet; MPV: Mean platelet volume; PT: Prothrombin time; FIB: Fibrinogen; APTT: Activated partial thromboplastin time; TT: Thrombin time; INR: International normalized ratio; CD: Crohn\'s disease; SD: Standard deviation.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study evaluated the impact of intestinal fistula on coagulation status in CD patients. PT in patients with intestinal fistula was significantly longer than patients without intestinal fistula in the overall cohort, females and males. Meanwhile, INR was higher in the overall intestinal fistula group and the corresponding subgroups. The blood PLT counts were less in the overall intestinal fistula group and the corresponding male group. With no doubt, patients with intestinal fistula also tended to have more operation history, no matter in females or in males. Logistic regression analysis identified that, in the overall cohort, intestinal fistula was significantly associated with prolonged PT, decreased amount of PLT, and increased operation history. In females, intestinal fistula was significantly associated with prolonged PT and increased operation history. In males, intestinal fistula was significantly associated with elevated INR, increased operation history, and decreased amount of PLT.

Intestinal fistula is one of the common complications of CD, and most patients are likely to need further surgery. Hence, it is critical to recognize accurately the coagulation status of CD patients complicated with intestinal fistula. Previous studies mainly focused on the coagulation state of CD patients without intestinal fistula, and most conclusions were that CD patients tended to have a hypercoagulable coagulation status, and the risk of VTE in CD patients was increased,\[[@ref2]\] as reported by Alatri *et al*. in 2016.\[[@ref9]\] The incidence of VTE in CD patients was not common (approximately 1--8%); however, it was a two- to four-fold higher risk of VTE than healthy people.\[[@ref10]\] A meta-analysis showed that the risks of VTE were similar in patients with ulcerative colitis and CD.\[[@ref11]\] What\'s more, the American Gastroenterological Association\[[@ref12][@ref13]\] and the European Crohn\'s and Colitis Organization\[[@ref14]\] recommended the prophylactic use of low-molecular-weight heparin in CD patients with active disease to avoid the risk of VTE.

PT in most patients complicated with intestinal fistula had prolonged PT in this study, and prolonged PT remained within the normal limits (12.61 ± 0.73 s in females, 13.37 ± 1.66 s in males). No serious coagulation disorders occurred during the research period. However, if coumarins, for example, warfarin, were prescribed for CD patients with intestinal fistula, impaired coagulation status would be aggravated. Therefore, the recommendations of guidelines about low-molecular-weight heparin were quite reasonable, and serious complications related to abnormal coagulation could be avoided as possible. We conducted this research to raise physicians' awareness about following the recommendations of guidelines and choosing the right coagulation-related medicine for CD patients with intestinal fistula.

Previous studies showed that administration of drugs may affect the coagulation status. For example, corticosteroids were confirmed to be associated with both hypocoagulation and hypercoagulation changes,\[[@ref15]\] and 5-aminosalicylic acid significantly reduced both spontaneous and thrombin-induced PLT activation.\[[@ref16]\] However, as there was no difference in drug use in the two groups, the impact of medications on changes in coagulation could be excluded in our study.

The ileum is an important site for Vitamin K absorption in humans,\[[@ref17]\] and ileal lesions are common in patients with CD.\[[@ref1]\] In this study, ileal lesions were present in most of the CD patients (44.7%). Vitamin K deficiency can result in a decrease in prothrombin (Factor II), Factor VII, Factor IX, and Factor X,\[[@ref18]\] which causes prolonged PT. In regard to the Vitamin K deficiency, it was a limit of this study due to the nature of retrospective study. The Vitamin K levels were not included in the database of CD patients. However, for the patients with risk of hemorrhage or being suspected of Vitamin K deficiency, prophylactic Vitamin K1 was commonly prescribed in our department (10 mg/d). In addition, 10 mg/d Vitamin K1 was a safe dose, which was proved by previous research.\[[@ref19]\] Further prospective research about Vitamin K deficiency in CD patients should be done in the future.

The decrease in Factor V and FIB is also associated with the coagulation function of CD. However, the study has shown that there were no significant differences in Factor V\[[@ref20]\] between patients with CD and controls.\[[@ref21]\] FIB levels in CD patients (4.91 g/L) were significantly higher than that of the control group (2.55 g/L, *P* \< 0.05). The PT might be prolonged as a result of disseminated intravascular coagulation (DIC). However, all patients were checked, and none of them had a diagnosis of DIC.

Nguyen and Sam\[[@ref22]\] reported that intestinal fistula was independently associated with a greater VTE risk. However, in the present study, intestinal fistula was significantly associated with prolonged PT. Nguyen and Sam\[[@ref22]\] did not show BMI data. The BMI of CD patients in the Western population was reported as 24.7 ± 4.3 kg/m^2^,\[[@ref23]\] which was higher than that of our study. A higher BMI was confirmed to be related to a greater VTE risk.\[[@ref24]\] This might partially explain the contradictory findings. Based on the previous research, the clinical manifestations of CD were notable in ethnic differences. Wang *et al*.\[[@ref25]\] reported that the PT in Chinese CD patients was significantly longer than healthy controls. Shen *et al*.\[[@ref3]\] also reported that PT in Chinese female CD patients was markedly longer than that of healthy controls. A study from Turkey\[[@ref20]\] also showed that PT in active IBD was longer than that in controls (12.5 ± 1.2 s vs. 11.5 ± 0.7 s, *P* \< 0.05). There are also ethnic variations in coagulation status. The risk of VTE was reported to be significantly lower in the East Asian cohorts, such as Chinese and Japanese.\[[@ref26]\] The above conclusions are opposite of those presented in most Western research. Thus, their location and ethnic variations in patients with CD should not be ignored, and this may require further research and analysis.

The impact of inflammation on coagulation status has been investigated in several studies, which showed that an inflammatory mechanism shifted the hemostatic balance to favor activation of coagulation.\[[@ref4][@ref5][@ref6][@ref7][@ref27]\] Despite there were no significant differences in CRP between groups and corresponding subgroups, in intestinal fistula group, PT correlated significantly with CRP (Pearson\'s *r* = 0.382, *P* = 0.001). This result verified the revealed relationships between inflammation and coagulation at some level. Nevertheless, the impact of inflammation on coagulation is complex and it remains unclear. The change in the coagulation status in CD patients complicated with intestinal fistula still cannot be confirmed by existing research.

For the patients who received intestinal fistula resections in our center, PT was obviously shorter after surgery. In the meanwhile, other indexes of coagulation status, such as PLT count, MPV, INR, FIB, and TT, were also changed. That meant that coagulation status was improved to some extent. However, the postoperative coagulation status was only explored in a short period (7 days) after surgery. Long-term follow-up would be conducted to explore the trends of changes in postoperative coagulation status in the future study.

Our study had some limitations. The data for some patients were incomplete. Therefore, statistical bias related to the missing data might be existed in this study. In addition, the patients were recruited from a single center and the sample size was small. Finally, because of the study\'s retrospective design, there was a potential risk of selection bias. Thus, our results might not completely reflect the impact of intestinal fistula on coagulation status in CD patients. Large-scale prospective multicenter clinical studies are needed to further confirm our conclusions.

In conclusion, intestinal fistula was significantly associated with impaired coagulation status in patients complicated with CD. Coagulation status could be improved after intestinal fistula resections.
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